Company: INTS
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0001628280-25-031311
Chunk: 1

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 1.01
Chunk 1
---
us Supplement”), filed with the Securities and Exchange Commission (“SEC”) on June 12, 2025, and an accompanying base prospectus that forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-280681), which was previously filed with the SEC on July 3, 2024 and declared effective on July 11, 2024.

The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement that is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P. C., counsel to the Company, delivered an opinion as to legality of the issuance and sale of the Shares in the Offering, a copy of which is filed as Exhibit 5.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 3.02. Unregistered Sales of Equity Securities.

Simultaneously with the closing of the Offering, pursuant to the Underwriting Agreement, the Company agreed to issue to the Underwriter and/or its designees, the Representative’s Warrants to purchase up to 383,812 shares of Common Stock (representing 5% of the aggregate number of Shares sold in the Offering), as a portion of the underwriting compensation payable to the Underwriter in connection with the Offering. The Representative’s Warrants will be exercisable during the period commencing upon issuance during the period commencing upon issuance until the five-year anniversary of the commencement of sales of the Shares in the Offering, at an exercise price per share of $0.375 (which is equal to 125% of the public offering price per share of the Common Stock in the Offering). The Representative’s Warrants have not and will not be registered and included in the Registration Statement or the related prospectus. As a result, the Representative’s Warrants provide for registration rights upon request, in certain cases. The Representative’s Warrants also contain a “cashless